About the Zage Lab

Principal Investigator

Peter E. Zage, MD, PhD is an associate professor-in-residence in pediatric oncology at UC San Diego Moores Cancer Center and attending hematologist/oncologist at Rady Children's Hospital-San Diego. Dr. Zage is an expert in the treatment of the pediatric solid tumors neuroblastoma and retinoblastoma, and his laboratory is focused on developing novel treatments and identifying novel targets for therapies for children with solid tumors. His primary laboratory projects include studies to better understand the pathways involved in the regulation of growth factor receptor trafficking and degradation in tumor cells and their role in tumor growth and treatment response in addition to studies to identify novel therapeutic targets and novel agents to use in combination with established therapies. Dr. Zage's laboratory has identified a key role for the ubiquitin ligase UBE4B in the regulation of receptor trafficking in neuroblastoma tumor cells, and he has also identified several promising novel targeted agents that have been translated into early phase clinical trials for children with relapsed and refractory solid tumors.

Laboratory Personnel

Contact information for our research team members is provided on the Team page. See Contact Us for mailing addresses and telephone numbers for the laboratory.

Funding

Current active funding support for research in the Zage laboratory is provided by: 
Hartwell Foundation Individual Biomedical Research Award
"Targeting Expression of an Enzyme Essential for Prevention of Neuroblastoma Growth and Metastasis"
Hyundai Hope on Wheels Hope Grant
"Cellular Networks in Neuroblastoma Differentiation"
Padres Pedal the Cause Investigator Initiated Clinical Trial (IIT) Award
"A National Phase I Study of Cabozantinib in Combination with 13-cis-Retinoic Acid in Children with Relapsed or Refractory Solid Tumors" 
UCSD Health Sciences Academic Senate Research Grant
"Allele Specific Expression Patterns in Neuroblastoma"
UC Cancer Research Coordinating Committee Faculty Seed Grant
"Targeting Novel Signaling Pathways for Neuroblastoma Therapy"
Exelixis, Inc.
"A National Phase I Study of Cabozantinib in Combination with 13-cis-Retinoic Acid in Children with Relapsed or Refractory Solid Tumors"
Aptose Biosciences, Inc. 
"Mechanisms of Efficacy of Apto-253 in Neuroblastoma Preclinical Models"

Clinical and Research Links

Moores Cancer Center Research
Rady Children's Hospital - San Diego